Exploring a new way to deliver radiation therapy that minimizes damage to healthy tissues.
Treatment Planning System for Electron FLASH radiation therapy
This study is exploring a new type of radiation therapy called FLASH radiotherapy, which gives a quick burst of high radiation to help treat tumors while causing less harm to healthy tissues, with the hope of making cancer treatments safer and more effective for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11287489 on NIH RePORTER |
What this research studies
This research investigates a novel approach to radiation therapy known as FLASH radiotherapy, which delivers ultra-high dose rates of radiation. The goal is to reduce damage to normal tissues while effectively targeting tumors, potentially improving treatment outcomes for cancer patients. By optimizing treatment plans for larger animals and humans, the research aims to demonstrate the advantages of FLASH-RT over conventional radiation therapy. This could lead to safer and more effective cancer treatments in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research would be cancer patients who require radiation therapy and are at risk of significant normal tissue damage.
Not a fit: Patients who are not undergoing radiation therapy or those with conditions that do not involve radiation treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce side effects from radiation therapy, improving the quality of life for cancer patients.
How similar studies have performed: While FLASH radiotherapy is a relatively novel approach, preliminary studies have shown promising results in reducing tissue damage compared to traditional methods.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Zhang, Rongxiao — University of Missouri-Columbia
- Study coordinator: Zhang, Rongxiao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.